DNAシーケンス市場- 世界の産業規模、シェア、動向、機会、予測、セグメント、製品タイプ別、技術別、用途別、エンドユーザー別、地域別、競合、2020年～2030年

DNAシーケンスの世界市場規模は、2024年に152億2,000万米ドルとなり、予測期間には467億2,000万米ドルに達すると予測され、2030年までのCAGRは20.53%です。

世界のDNAシーケンス市場は、技術の進歩、ゲノミクスにおけるアプリケーションの増加、精密医療に対する需要の高まりにより、著しい成長を遂げています。シーケンス技術、特に次世代シーケンス（NGS）は、ハイスループット、コスト効率、高速シーケンス機能を提供し、ゲノミクスの分野に革命をもたらしました。腫瘍学、遺伝学、生殖医療などさまざまな研究領域にDNAシーケンスが統合されたことで、市場での採用がさらに加速しました。単一細胞シーケンシングや第3世代シーケンシング技術など、より高度で正確なシーケンス手法の開発により、DNAシーケンスの精度と応用範囲は拡大し続けており、臨床診断や個別化ヘルスケアに不可欠なツールとなっています。

DNAシーケンス市場の主な成長促進要因としては、遺伝性疾患、がん、その他の慢性疾患の世界の有病率の上昇、ゲノム研究に対する政府の資金提供やイニシアチブの増加などが挙げられます。個々の患者に合わせた治療を行うために詳細な遺伝子情報を必要とする精密医療の需要は、市場拡大に大きく寄与しています。さらに、疾病の早期発見、薬剤開発、個別化治療に対するニーズの高まりが、病院、診療所、研究機関全体でDNAシーケンスの採用を後押ししています。また、複雑なシーケンスデータの解析や解釈に役立つバイオインフォマティクスツールの強化も、より正確な診断や治療法の開拓を可能にし、市場の成長を促進する上で重要な役割を果たしています。

しかし、市場は高度なシーケンス技術に関連する高コストという課題に直面しており、特定の地域や小規模なヘルスケアプロバイダーにとってはアクセスが制限される可能性があります。シーケンシングデータの複雑さと、結果を解釈するための専門的な専門知識の必要性が、さらなるハードルとなっています。さらに、プライバシーや遺伝子情報の悪用の可能性など、ゲノムデータをめぐる倫理的な懸念も引き続き議論されています。市場が拡大するにつれ、より安価なシーケンス技術の開発、データ解釈ツールの改善、ゲノム情報の倫理的かつ責任ある利用を保証するための明確な規制枠組みを通じて、これらの課題に対処することが極めて重要になります。こうした課題にもかかわらず、腫瘍学、個別化医療、遺伝子スクリーニングなどの分野でDNAシーケンスの利用が拡大していることは、将来の市場成長にとって大きな機会となります。

主な市場促進要因

遺伝性疾患およびがんの発生率の増加

2021年には、鎌状赤血球症の患者数は2000年から41.4%増加し、約774万人に達します。

ハンチントン病はまれではあるが、世界の有病率は10万人当たり4.88人まで増加しています。

ゲノム研究と応用の拡大

例えば、英国政府は2022年12月、世界で最も進んだゲノム医療システムの構築を目指し、ゲノム研究に2億1,937万米ドルを投資すると発表しました。

シーケンス技術の技術的進歩

主な市場課題

シーケンス技術の高コスト

倫理的、法的、プライバシーに関する懸念

主な市場動向

個別化医療と精密医療

遺伝子スクリーニングにおける利用の増加

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界のDNAシーケンス市場の展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 製品タイプ別（機器、消耗品、サービス）
  • 技術別（サンガーシーケンス、次世代シーケンス（NGS）、第三世代シーケンス、その他）
  • 用途別（診断、調査、個別化医療、法医学検査、その他）
  • エンドユーザー別（病院・ヘルスケア機関、学術調査機関、製薬・バイオテクノロジー企業、その他）
  • 企業別（2024）
  • 地域別
• 市場マップ

第6章 北米のDNAシーケンス市場の展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • メキシコ
  • カナダ

第7章 欧州のDNAシーケンス市場の展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • ドイツ
  • 英国
  • イタリア
  • スペイン

第8章 アジア太平洋地域のDNAシーケンス市場の展望

• 市場規模・予測
• 市場シェア・予測
• アジア太平洋地域：国別分析
  • インド
  • 韓国
  • 日本
  • オーストラリア

第9章 南米のDNAシーケンス市場の展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカのDNAシーケンス市場の展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 合併と買収（ある場合）
• 製品の発売（ある場合）
• 最近の動向

第13章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第14章 競合情勢

• Thermo Fisher Scientific Inc.
• Agilent Technologies, Inc.
• Bio-Rad Laboratories, Inc.
• F. Hoffmann-La Roche Ltd.
• Illumina, Inc.
• QIAGEN N.V.
• Merck KGaA
• Macrogen, Inc.
• PerkinElmer, Inc.
• Eurofins Scientific Limited

第15章 戦略的提言

第16章 調査会社について・免責事項

Global DNA Sequencing Market was valued at USD 15.22 Billion in 2024 and is expected to reach USD 46.72 Billion in the forecast period with a CAGR of 20.53% through 2030. The Global DNA Sequencing Market has experienced remarkable growth due to technological advancements, increasing applications in genomics, and rising demand for precision medicine. Sequencing technologies, particularly Next-Generation Sequencing (NGS), have revolutionized the field of genomics, offering high-throughput, cost-effective, and faster sequencing capabilities. The integration of DNA sequencing into various research domains such as oncology, genetics, and reproductive health has further accelerated market adoption. The development of more advanced and accurate sequencing methods, such as single-cell sequencing and third-generation sequencing technologies, continues to enhance the precision and applications of DNA sequencing, making it an indispensable tool in clinical diagnostics and personalized healthcare.

Key growth drivers for the DNA sequencing market include the rising global prevalence of genetic disorders, cancer, and other chronic diseases, as well as increased government funding and initiatives for genomic research. The demand for precision medicine, which requires detailed genetic information to tailor treatments to individual patients, is a significant factor contributing to market expansion. Furthermore, the growing need for early disease detection, drug development, and personalized therapies has propelled the adoption of DNA sequencing across hospitals, clinics, and research institutions. Enhanced bioinformatics tools that help in analyzing and interpreting complex sequencing data have also played a crucial role in facilitating the market's growth by enabling more accurate diagnostics and therapeutic development.

However, the market faces challenges related to the high costs associated with advanced sequencing technologies, which can limit accessibility in certain regions and for smaller healthcare providers. The complexity of sequencing data and the requirement for specialized expertise to interpret results pose additional hurdles. Furthermore, ethical concerns surrounding genomic data, including privacy and the potential misuse of genetic information, continue to be debated. As the market expands, it will be crucial to address these challenges through the development of more affordable sequencing technologies, improved data interpretation tools, and clearer regulatory frameworks to ensure ethical and responsible use of genomic information. Despite these challenges, the expanding use of DNA sequencing in areas like oncology, personalized medicine, and genetic screening offers significant opportunities for future market growth.

Key Market Drivers

Increasing Incidence of Genetic Disorders and Cancer

The increasing incidence of genetic disorders and cancer is a significant driver for the Global DNA Sequencing Market. Genetic disorders, such as cystic fibrosis, sickle cell anemia, and Huntington's disease, affect millions worldwide. For instance, the World Health Organization estimates that 10 out of every 1,000 people are affected by genetic disorders, translating to between 70 million and 80 million individuals globally.

In 2021, the number of people living with sickle cell disease globally increased by 41.4% from 2000, reaching approximately 7.74 million.

Huntington's disease, though rarer, has seen a pooled global prevalence rise to 4.88 per 100,000 individuals.

Cancer prevalence has also escalated, with the World Health Organization reporting approximately 19.3 million new cancer cases and 10 million cancer-related deaths worldwide in 2020. This rising burden underscores the need for advanced diagnostic tools. DNA sequencing enables the identification of genetic mutations associated with various cancers, facilitating early detection and personalized treatment strategies. The growing recognition of the genetic underpinnings of many cancers has led to increased adoption of sequencing technologies in oncology.

The rising prevalence of these conditions has heightened the demand for DNA sequencing technologies, which are instrumental in diagnosing genetic disorders and informing targeted cancer therapies. As awareness of the genetic basis of diseases grows, healthcare providers are increasingly integrating sequencing into clinical practice to enhance patient outcomes. Consequently, the escalating incidence of genetic disorders and cancer is a pivotal factor propelling the expansion of the DNA sequencing market.

Expansion of Genomic Research and Applications

The expansion of genomic research and its growing applications across various sectors are driving the growth of the Global DNA Sequencing Market. Advances in next-generation sequencing (NGS) technologies have made it possible to decode genetic information faster, more accurately, and at a lower cost, enabling a wide range of applications in healthcare, agriculture, forensic science, and biotechnology. Governments and private organizations are heavily investing in genomic research initiatives to better understand genetic diseases, develop targeted therapies, and advance precision medicine. Large-scale projects such as the Human Genome Project and national genome sequencing initiatives have created significant momentum in the adoption of sequencing technologies.

In healthcare, the increasing focus on personalized medicine and pharmacogenomics has fueled demand for DNA sequencing in diagnosing genetic disorders, predicting disease susceptibility, and optimizing treatment strategies. The integration of sequencing with artificial intelligence and bioinformatics has enhanced the interpretation of genetic data, leading to more precise insights into disease mechanisms and drug responses. The use of DNA sequencing in oncology for cancer profiling and treatment selection has further strengthened its role in clinical settings.

Beyond healthcare, DNA sequencing is playing a crucial role in agriculture and food safety by enabling the development of genetically modified crops, improving disease resistance, and enhancing food traceability. In forensic science, sequencing is aiding in criminal investigations, ancestry determination, and disaster victim identification. With continuous advancements in sequencing platforms, declining costs, and increasing government and private sector investments, the applications of DNA sequencing are expected to expand further, making genomic research a key driver of market growth.

For instance, in December 2022, the UK government announced a USD 219.37 million investment in genomics research, aiming to create the most advanced genomic healthcare system in the world.

Similarly, the U.S. National Institutes of Health (NIH) allocated USD 320.4 million for Research Project Grants (RPGs) in fiscal year 2023, supporting a total of 414 awards, including those related to genomic research. These substantial investments underscore the commitment to advancing genomic research and its applications, further propelling the growth of the DNA sequencing market.

Technological Advancements in Sequencing Technologies

Technological advancements in sequencing technologies have significantly accelerated the growth of the Global DNA Sequencing Market. The evolution from traditional sequencing methods to more advanced platforms, such as Next-Generation Sequencing (NGS) and Third-Generation Sequencing, has enabled faster, more accurate, and cost-effective analysis of genomes. These innovations have substantially increased the throughput and scalability of sequencing, making it more accessible to a wider range of applications, including clinical diagnostics, research, and personalized medicine.

NGS technologies, for instance, allow researchers to sequence entire genomes or targeted regions with high accuracy and at a fraction of the cost compared to earlier methods like Sanger sequencing. As a result, NGS has become a vital tool in understanding genetic disorders, detecting rare diseases, and identifying biomarkers for drug development. The reduction in sequencing costs, driven by advancements such as illumina sequencing and single-molecule real-time sequencing, has made it possible for healthcare systems, academic institutions, and research laboratories to implement DNA sequencing on a broader scale.

Additionally, the development of more advanced data analysis software and algorithms has improved the ability to interpret complex genomic data. These innovations have expanded the potential of DNA sequencing beyond traditional applications, supporting the rise of precision medicine, where treatments are tailored based on individual genetic profiles. As sequencing technologies continue to evolve, they offer greater speed, accuracy, and efficiency, driving significant demand in various sectors, including diagnostics, pharmaceuticals, and biotechnology. This continuous innovation is a key driver for the global DNA sequencing market, with ongoing advancements expected to further enhance its capabilities and applications.

Key Market Challenges

High Costs of Sequencing Technologies

The Global DNA Sequencing Market faces several challenges, notably the high costs associated with sequencing technologies. Despite significant advancements, the expense of sequencing remains a substantial barrier to widespread adoption, particularly in resource-constrained settings. For instance, while the cost of sequencing a human genome has decreased from approximately USD 3 billion during the Human Genome Project to around USD 600 in recent years, it still represents a significant investment for many institutions and healthcare providers.

The high costs are attributed to several factors, including the need for specialized equipment, consumables, and skilled personnel. Next-Generation Sequencing (NGS) platforms, which offer high throughput and accuracy, require substantial initial investment and ongoing maintenance expenses. Additionally, the complexity of data analysis necessitates advanced computational resources and expertise, further increasing the overall cost of sequencing projects.

These financial barriers limit the accessibility of DNA sequencing technologies, particularly in developing regions and smaller research institutions. The disparity in access to advanced sequencing technologies can hinder global efforts in genomics research, personalized medicine, and the development of targeted therapies. Addressing the high costs associated with sequencing technologies is crucial to ensure equitable access to genomic advancements and to fully realize the potential benefits of DNA sequencing in healthcare and research.

Ethical, Legal, and Privacy Concerns

Ethical, legal, and privacy concerns represent a significant challenge in the Global DNA Sequencing Market. The increasing adoption of DNA sequencing technologies in healthcare and research has raised questions about how genetic data is collected, stored, and shared. One of the primary concerns revolves around data privacy, as DNA contains highly personal and sensitive information. Unauthorized access or breaches in data security could lead to the misuse of genetic data, compromising individuals' privacy and confidentiality. Regulatory frameworks governing data storage and usage are still evolving, and this lack of consistency and clear regulations increases uncertainty for stakeholders in the market.

The ethical issues surrounding DNA sequencing are complex. There is growing concern over the potential for genetic information to be used for purposes beyond healthcare, such as insurance discrimination or employment bias. The ability to predict genetic diseases may also create ethical dilemmas about pre-emptive testing, especially when it comes to minors or individuals without symptoms. The notion of genetic modification or altering genetic material in embryos also raises moral questions about the extent of intervention in natural biological processes.

Legal challenges also persist in the form of intellectual property rights, consent procedures, and ownership of genetic data. With numerous entities involved in sequencing and analyzing genetic data, clarifying who holds the rights to genetic information is increasingly important. Countries and regions have varying regulations regarding genetic data use, and aligning international standards is difficult. These ethical, legal, and privacy concerns could hinder the widespread adoption of DNA sequencing technologies and delay further advancements in genomics.

Key Market Trends

Personalized and Precision Medicine

The trend of Personalized and Precision Medicine is significantly transforming the Global DNA Sequencing Market. Personalized and precision medicine involve tailoring medical treatment to individual characteristics, such as genetic makeup, lifestyle, and environment. DNA sequencing plays a pivotal role in this approach by providing detailed genetic information, which helps in understanding how an individual's unique genetic profile can influence their response to treatments and susceptibility to diseases. This trend is increasingly becoming central to the healthcare landscape as it allows for more effective and targeted therapies, particularly in oncology, cardiology, and rare genetic disorders.

With advancements in Next-Generation Sequencing (NGS) technologies, it has become more affordable and accessible to integrate genetic data into clinical practice. DNA sequencing enables clinicians to identify genetic mutations that may not be apparent through traditional diagnostic methods, improving early detection and the ability to predict health risks with greater accuracy. This ability to identify genetic predispositions is especially valuable in diseases like cancer, where understanding mutations allows for the development of customized treatment plans that are more likely to succeed.

The adoption of personalized medicine is also being driven by an increasing focus on improving patient outcomes and reducing healthcare costs. By identifying the most effective treatment options based on an individual's genetic makeup, unnecessary treatments can be avoided, leading to more efficient use of healthcare resources. As awareness of the benefits of personalized healthcare continues to grow, the demand for DNA sequencing technologies will rise, making it one of the key trends influencing the market's expansion in the coming years.

Increased Use in Genetic Screening

The increased use of DNA sequencing in genetic screening is one of the prominent trends driving growth in the Global DNA Sequencing Market. Genetic screening involves analyzing an individual's DNA to detect genetic disorders, inherited conditions, and predispositions to diseases, playing a vital role in early disease detection and prevention. As awareness of genetic risks and personalized medicine increases, more individuals are seeking genetic testing to understand their potential health risks, prompting healthcare providers to incorporate DNA sequencing as a key diagnostic tool.

This trend is particularly significant in oncology, where DNA sequencing is used to identify genetic mutations associated with cancer risk and to guide treatment decisions. It also has applications in prenatal screening, carrier screening for genetic disorders, and pharmacogenomics, which helps in determining the most effective medications based on an individual's genetic makeup. As the cost of DNA sequencing continues to decrease and technologies like Next-Generation Sequencing (NGS) become more accessible, genetic screening is no longer limited to research settings and is increasingly offered as a routine diagnostic tool in clinical practices.

The growing emphasis on preventive healthcare and personalized medicine is contributing to the expansion of genetic screening. As healthcare systems worldwide seek more effective ways to manage long-term diseases and reduce healthcare costs, early detection of genetic risks allows for timely interventions, improving patient outcomes. The ability to offer personalized treatment plans based on genetic data is also driving demand for DNA sequencing in clinical genetic screening. This trend is expected to continue gaining momentum, further establishing DNA sequencing as a cornerstone in modern healthcare and diagnostics.

Segmental Insights

Product Type Insights

Based on the Product Type, Consumables emerged as the dominant segment in the Global DNA Sequencing Market in 2024. This is due to several key factors. Consumables such as reagents, chemicals, and kits are essential components required for the DNA sequencing process. These consumables are used repeatedly across various sequencing workflows, making them a consistent source of revenue in the market. As the demand for DNA sequencing services continues to rise, the need for consumables increases, particularly in research and clinical settings where sequencing is increasingly integrated into diagnostics and personalized medicine. The widespread adoption of Next-Generation Sequencing (NGS) technologies has further fueled the demand for consumables. NGS relies on a range of high-quality consumables, such as sequencing primers, probes, and adapters, to perform sequencing reactions accurately and efficiently. Additionally, the growth of genomic research and clinical applications such as cancer genomics, genetic screening, and precision medicine has contributed to the substantial demand for consumables. These consumables are necessary for maintaining the high throughput, accuracy, and reliability of sequencing platforms, making them integral to the DNA sequencing process. As a result, the consumables segment is expected to continue dominating the market, driven by their essential role in the sequencing process and the increasing number of sequencing applications globally.

Application Insights

Based on the Application, Diagnostics emerged as the dominant segment in the Global DNA Sequencing Market in 2024. This is due to the growing importance of genetic testing in disease detection, personalized medicine, and early diagnosis. DNA sequencing plays a critical role in identifying genetic mutations, abnormalities, and predispositions that can lead to various health conditions, including cancer, genetic disorders, and infectious diseases. The increased adoption of DNA sequencing in clinical diagnostics has made it an invaluable tool for improving patient care, providing more accurate diagnoses, and enabling the development of tailored treatment plans. Advancements in sequencing technologies, such as Next-Generation Sequencing (NGS), have made genetic testing more accessible, affordable, and efficient, further driving the growth of the diagnostics segment. Additionally, the growing emphasis on personalized medicine, which relies on genetic data to determine the best course of treatment for individuals, has further boosted the demand for DNA sequencing in diagnostic applications. With DNA sequencing offering the ability to analyze entire genomes or targeted genetic regions, it is increasingly being utilized in oncology for tumor profiling, pharmacogenomics for drug response prediction, and rare genetic disease diagnosis. The ability of DNA sequencing to provide precise and actionable insights into an individual's health is making it the dominant application in the market, with expanding use cases in clinical diagnostics globally.

Regional Insights

North America emerged as the dominant region in the Global DNA Sequencing Market in 2024. This is due to several key factors. The region benefits from advanced healthcare infrastructure, strong research and development activities, and a high level of investment in genomics and biotechnology. The presence of major players in the DNA sequencing market, such as Illumina, Thermo Fisher Scientific, and Pacific Biosciences, has established North America as a hub for innovation in sequencing technologies. Additionally, the growing demand for personalized medicine, precision diagnostics, and genomic research has further contributed to the market's expansion in the region. The robust healthcare system in North America, especially in the United States, has facilitated the adoption of DNA sequencing technologies across clinical settings. DNA sequencing is increasingly used in diagnostics, oncology, genetic testing, and pharmacogenomics, leading to higher demand in both research and healthcare applications. Furthermore, the strong emphasis on personalized medicine and the growing number of government initiatives and funding for genomic research are driving market growth in the region. The regulatory environment in North America, which supports the approval and commercialization of new genomic technologies, also plays a crucial role in maintaining the region's dominance in the DNA sequencing market. These factors combined have made North America the leading region in the global market in 2024.

Key Market Players

• Thermo Fisher Scientific Inc.
• Agilent Technologies, Inc.
• Bio-Rad Laboratories, Inc.
• F. Hoffmann-La Roche Ltd.
• Illumina, Inc.
• QIAGEN N.V.
• Merck KGaA
• Macrogen, Inc.
• PerkinElmer, Inc.
• Eurofins Scientific Limited

Report Scope:

In this report, the Global DNA Sequencing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

DNA Sequencing Market, By Product Type:

• Instruments
• Consumables
• Services

DNA Sequencing Market, By Technology:

• Sanger Sequencing
• Next-Generation Sequencing (NGS)
• Third-Generation Sequencing
• Others

DNA Sequencing Market, By Application:

• Diagnostics
• Research
• Personalized Medicine
• Forensic Testing
• Others

DNA Sequencing Market, By End User:

• Hospitals and Healthcare Organizations
• Academics and Research Institutions
• Pharmaceutical and Biotechnology Companies
• Others

DNA Sequencing Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global DNA Sequencing Market.

Available Customizations:

Global DNA Sequencing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, and Trends

4. Voice of Customer

5. Global DNA Sequencing Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product Type (Instruments, Consumables, Services)
  • 5.2.2. By Technology (Sanger Sequencing, Next-Generation Sequencing (NGS), Third-Generation Sequencing, Others)
  • 5.2.3. By Application (Diagnostics, Research, Personalized Medicine, Forensic Testing, Others)
  • 5.2.4. By End User (Hospitals and Healthcare Organizations, Academics and Research Institutions, Pharmaceutical and Biotechnology Companies, Others)
  • 5.2.5. By Company (2024)
  • 5.2.6. By Region
• 5.3. Market Map

6. North America DNA Sequencing Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product Type
  • 6.2.2. By Technology
  • 6.2.3. By Application
  • 6.2.4. By End User
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States DNA Sequencing Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product Type
      • 6.3.1.2.2. By Technology
      • 6.3.1.2.3. By Application
      • 6.3.1.2.4. By End User
  • 6.3.2. Mexico DNA Sequencing Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product Type
      • 6.3.2.2.2. By Technology
      • 6.3.2.2.3. By Application
      • 6.3.2.2.4. By End User
  • 6.3.3. Canada DNA Sequencing Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product Type
      • 6.3.3.2.2. By Technology
      • 6.3.3.2.3. By Application
      • 6.3.3.2.4. By End User

7. Europe DNA Sequencing Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product Type
  • 7.2.2. By Technology
  • 7.2.3. By Application
  • 7.2.4. By End User
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France DNA Sequencing Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product Type
      • 7.3.1.2.2. By Technology
      • 7.3.1.2.3. By Application
      • 7.3.1.2.4. By End User
  • 7.3.2. Germany DNA Sequencing Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product Type
      • 7.3.2.2.2. By Technology
      • 7.3.2.2.3. By Application
      • 7.3.2.2.4. By End User
  • 7.3.3. United Kingdom DNA Sequencing Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product Type
      • 7.3.3.2.2. By Technology
      • 7.3.3.2.3. By Application
      • 7.3.3.2.4. By End User
  • 7.3.4. Italy DNA Sequencing Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product Type
      • 7.3.4.2.2. By Technology
      • 7.3.4.2.3. By Application
      • 7.3.4.2.4. By End User
  • 7.3.5. Spain DNA Sequencing Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product Type
      • 7.3.5.2.2. By Technology
      • 7.3.5.2.3. By Application
      • 7.3.5.2.4. By End User

8. Asia-Pacific DNA Sequencing Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product Type
  • 8.2.2. By Technology
  • 8.2.3. By Application
  • 8.2.4. By End User
  • 8.2.5. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China DNA Sequencing Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product Type
      • 8.3.1.2.2. By Technology
      • 8.3.1.2.3. By Application
      • 8.3.1.2.4. By End User
  • 8.3.2. India DNA Sequencing Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product Type
      • 8.3.2.2.2. By Technology
      • 8.3.2.2.3. By Application
      • 8.3.2.2.4. By End User
  • 8.3.3. South Korea DNA Sequencing Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product Type
      • 8.3.3.2.2. By Technology
      • 8.3.3.2.3. By Application
      • 8.3.3.2.4. By End User
  • 8.3.4. Japan DNA Sequencing Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product Type
      • 8.3.4.2.2. By Technology
      • 8.3.4.2.3. By Application
      • 8.3.4.2.4. By End User
  • 8.3.5. Australia DNA Sequencing Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product Type
      • 8.3.5.2.2. By Technology
      • 8.3.5.2.3. By Application
      • 8.3.5.2.4. By End User

9. South America DNA Sequencing Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product Type
  • 9.2.2. By Technology
  • 9.2.3. By Application
  • 9.2.4. By End User
  • 9.2.5. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil DNA Sequencing Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product Type
      • 9.3.1.2.2. By Technology
      • 9.3.1.2.3. By Application
      • 9.3.1.2.4. By End User
  • 9.3.2. Argentina DNA Sequencing Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product Type
      • 9.3.2.2.2. By Technology
      • 9.3.2.2.3. By Application
      • 9.3.2.2.4. By End User
  • 9.3.3. Colombia DNA Sequencing Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product Type
      • 9.3.3.2.2. By Technology
      • 9.3.3.2.3. By Application
      • 9.3.3.2.4. By End User

10. Middle East and Africa DNA Sequencing Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product Type
  • 10.2.2. By Technology
  • 10.2.3. By Application
  • 10.2.4. By End User
  • 10.2.5. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa DNA Sequencing Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product Type
      • 10.3.1.2.2. By Technology
      • 10.3.1.2.3. By Application
      • 10.3.1.2.4. By End User
  • 10.3.2. Saudi Arabia DNA Sequencing Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product Type
      • 10.3.2.2.2. By Technology
      • 10.3.2.2.3. By Application
      • 10.3.2.2.4. By End User
  • 10.3.3. UAE DNA Sequencing Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product Type
      • 10.3.3.2.2. By Technology
      • 10.3.3.2.3. By Application
      • 10.3.3.2.4. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Porters Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Products

14. Competitive Landscape

• 14.1. Thermo Fisher Scientific Inc.
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Financials (As Reported)
  • 14.1.5. Recent Developments
  • 14.1.6. Key Personnel Details
  • 14.1.7. SWOT Analysis
• 14.2. Agilent Technologies, Inc.
• 14.3. Bio-Rad Laboratories, Inc.
• 14.4. F. Hoffmann-La Roche Ltd.
• 14.5. Illumina, Inc.
• 14.6. QIAGEN N.V.
• 14.7. Merck KGaA
• 14.8. Macrogen, Inc.
• 14.9. PerkinElmer, Inc.
• 14.10. Eurofins Scientific Limited

15. Strategic Recommendations

16. About Us & Disclaimer